1 unchanged sentence
Rule 10b - 5 ( 1 ) Trading Plans.
−Removed: During the three -month period ended March 31, 2026 , no director or officer of the Company adopted or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” as each term is defined in Item 408 (a) of Regulation S-K.
+Added: During the three -month period ended June 30, 2026 , no director or officer of the Company adopted or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” as each term is defined in Item 408 (a) of Regulation S-K.
The exhibits listed on the Exhibit Index are either filed or furnished with this report or incorporated herein by reference.
EXHIBIT INDEX
−Removed: Asset Purchase Agreement dated February 27, 2026 by and among Pierre Fabre Medicament Sas and the Registrant (portions of the exhibit have been redacted).
+Added: Sixth Amendment to Credit Agreement by and among the Company and SWK Funding LLC dated as of April 6, 2026
+Added: Asset Purchase Agreement dated May 18, 2026 by and among Knight Therapeutics Europe S.A.
+Added: and the Registrant (portions of the exhibit have been redacted).
+Added: Offer Letter Agreement by and between the Registrant and Judith Matthews, dated as of June 3, 2026
Certification of President and Chief Executive Officer (Principal Executive Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial information from the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL):
+Added: The following financial information from the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL):
(i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations, (iii) the Condensed Statements of Stockholders’ Equity, (iv) the Condensed Statements of Cash Flows and (v) Notes to Condensed Financial Statements.
4 unchanged sentences
ETON PHARMACEUTICALS, INC.
+Added: August 13, 2026
President and Chief Executive Officer
(Principal Executive Officer)
+Added: /s/ Judith M.
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.